Chinese Journal of Child Health Care ›› 2022, Vol. 30 ›› Issue (2): 176-180.DOI: 10.11852/zgetbjzz2021-0030

• Review • Previous Articles     Next Articles

Research progress in biomarkers in the risk of bronchopulmonary dysplasia

CHEN Xiang-fei, QU Shu-qiang   

  1. Department of Pediatrics,the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150086, China
  • Received:2021-01-07 Revised:2021-04-13 Online:2022-02-10 Published:2022-02-25
  • Contact: QU Shu-qiang,


陈祥菲, 曲书强   

  1. 哈尔滨医科大学第二附属医院儿内科,黑龙江 哈尔滨 150086
  • 通讯作者: 曲书强,
  • 作者简介:陈祥菲(1982-)男,山东人,主治医师,硕士研究生,主要研究方向为新生儿及呼吸系统疾病。

Abstract: Bronchopulmonary dysplasia (BPD) is mainly found in very low or extra-low birth weight infants, or newborns who take a long time on ventilator and have difficulty in removing ventilator. BPD is one of the causes of neonatal mortality, which seriously affects the health status of children and also causes a heavy economic burden to families and society. At present, there are no specific drugs and effective interventions at home and abroad, so prevention and assessment of the occurrence of this disease are crucial. The occurrence and risk assessment of BPD by molecular biomarkers is currently a hot topic of researches at home and abroad, which plays an important guiding role and has practical significance. This paper reviews the risk and assessment of molecular biomarkers for the development of BPD, in order to provide new ideas on how to predict and assess the occurrence of BPD.

Key words: bronchopulmonary, dysplasia biomarkers, premature infants

摘要: 支气管肺发育不良(BPD)主要见于极低或超低出生体重儿,或是上呼吸机时间长、下呼吸机困难的新生儿;是新生儿致死的原因之一,严重影响儿童的健康状况,也给家庭和社会造成了沉重的经济负担。目前在治疗上,国内外还没有特异性药物和有效的干预措施,因此预防和评估本病的发生显得至关重要;目前分子生物标志物对BPD的发生及风险评估是国内外学者研究的热点,具有重要的指导作用和现实意义,本文针对分子生物标志物对BPD的发生风险和评估展开综述,以期为临床如何预测和评估BPD的发生提供新思路。

关键词: 支气管肺发育不良, 生物标志物, 早产儿

CLC Number: